|
시장보고서
상품코드
2051409
골암 치료제 시장 : 약물 유형별, 질환 적응증별, 유통 채널별, 지역별Bone Cancer Drugs Market, By Drug Type, By Disease Indication, By Distribution Channel, and By Region |
||||||
골암 치료제 시장은 2026년에 15억 20만 달러로 추정되며, 2033년까지 21억 6,780만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 5.4%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 15억 20만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 5.40% | 2033년 시장 규모 예측: | 21억 6,780만 달러 |
암은 매우 침습적이고 장기적인 경과로 인해 사망률이 높은 가장 흔한 치명적인 만성질환 중 하나입니다. 골암은 뼈 조직이 통제할 수 없는 형태로 증식하는 암의 일종입니다. 골암 시장은 원발성 골암, 전이성 골암 등 골암의 종류에 따라 구분됩니다. 원발성 골암은 뼈와 관련 조직의 급속하고 통제할 수 없는 증식으로 인해 발생하는 암의 일종입니다. 반면 전이성 골암은 체내 다른 부위에서 발생한 암이 뼈로 전이된 것을 말합니다. 골암은 골육종, 유잉육종, 연골육종, 척삭종, 섬유육종, 아담틴종으로 나뉩니다.
시장 역학
골암에 대한 신약 출시와 규제 당국의 승인 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2021년 5월 브리스톨마이어스스퀴브와 블루버드 바이오는 다제내성 재발 및 불응성 다발성 골수종 환자를 대상으로 한 이데카부타게네 비클셀(ide-cel, bb2121)의 생물학적 제제 승인 신청(BLA)에 대해 미국 식품의약국(FDA) 으로부터 접수 거부 통지를 받았다고 발표했습니다. 또한, 2016년 4월에는 애드벡시스가 수술적 절제 가능한 골육종 치료를 목적으로 HER2 발현 암을 표적으로 하는 Lm기술 면역항암제 ADXS-HER2에 대해 미국 FDA로부터 패스트트랙 지정을 받았습니다. 미국 FDA의 패스트트랙 지정을 통해 우리는 개발 과정을 가속화하여 환자들에게 더 빠르고 더 나은 치료법을 제공할 수 있게 되었습니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 본 보고서에서는 세계 골암 치료제 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등 다양한 매개 변수를 기반으로 분석하여 소개합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 골암 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 골암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 골암 치료제 시장 : 약물 유형별, 2021-2033년
제5장 세계의 골암 치료제 시장 : 질환 적응증별, 2021-2033년
제6장 세계의 골암 치료제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 골암 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.06.16Bone Cancer Drugs Market is estimated to be valued at USD 1,500.2 Mn in 2026 and is expected to reach USD 2,167.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,500.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.40% | 2033 Value Projection: | USD 2,167.8 Mn |
Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing's sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2021, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2021. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA's Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global bone cancer drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market.
Market Segmentation
- By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
- By Disease Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing's Sarcoma
- By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co.
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Market Trends
- Regulatory Scenario
- New Product Launches/Approvals
- Merger, Acquisition and Collaboration Scenario
- PEST Analysis
- PORTER's Analysis
4. Global Bone Cancer Drugs Market, By Drug Type, 2021- 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
5. Global Bone Cancer Drugs Market, By Disease Indication, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
- Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
- Chondrosarcoma
- Introduction
- Ewing's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Bone Cancer Drugs Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
7. Global Bone Cancer Drugs Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Advaxis, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cellectar Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- OPKO Health, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Debiopharm Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analyst Views
- Advaxis, Inc.
9. Section
- References
- Research Methodology
- About us and Sales Contact
